What's happened to elinogrel? Novartis misses former hot prospect off blockbuster list
This article was originally published in Scrip
Novartis appears to be re-assessing the potential of the antiplatelet candidate elinogrel that it licensed for up to $575 million from Portola Pharmaceuticals in 2009. It was conspicuous by its absence from a sample list of seven potential blockbusters currently in the Swiss major's pipeline at its second-quarter results presentation yesterday.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.